SCHEMBL27249

SCHEMBL27249

N/C=C\C(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL899065 1.00
SCHEMBL3188709 1.00
Ammonia Solution, Strong SCHEMBL8436490 0.96
SCHEMBL156118 0.79
SCHEMBL245241 0.79
SCHEMBL156117 0.79
SCHEMBL17565650 0.76
Hydrochloric Acid SCHEMBL9156886 0.75
Charcoal, Activated SCHEMBL6391496 0.75 ALDH1A1 (0.47)
Hydrochloric Acid SCHEMBL9156875 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119955492-A Gel blocking agent and preparation method and application thereof 中国石油化工股份有限公司 2025-05-09 CN claimed
CN-119955501-A High-temperature-resistant gel composition and preparation method and application thereof 中国石油化工股份有限公司 2025-05-09 CN claimed
CN-119955491-A Self-repairing gel plugging agent and preparation method and application thereof 中国石油化工股份有限公司 2025-05-09 CN claimed
CN-119955492-A Gel blocking agent and preparation method and application thereof 中国石油化工股份有限公司 2025-05-09 CN disclosed
CN-119955491-A Self-repairing gel plugging agent and preparation method and application thereof 中国石油化工股份有限公司 2025-05-09 CN disclosed
CN-119955501-A High-temperature-resistant gel composition and preparation method and application thereof 中国石油化工股份有限公司 2025-05-09 CN disclosed
US-20240025877-A1 PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED 2024-01-25 US disclosed
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
EP-4100015-A1 COMBINATION THERAPY FOR TREATING MPS1 Gain Therapeutics SA (CH) 2022-12-14 EP disclosed
CN-115397423-A Combination therapy for the treatment of MPS1 增益治疗股份有限公司 2022-11-25 CN disclosed
WO-2010007800-A1 NOVEL URACIL COMPOUND HAVING AMIDE STRUCTURE AND SALT THEREOF 大鵬薬品工業株式会社 (JP) 2010-01-21 WO disclosed
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors GEGE CHRISTIAN 2008-10-23 US disclosed
US-20080221095-A1 Metalloprotease inhibitors containing a heterocyclic moiety ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-09-11 US disclosed
US-20080221128-A1 Metalloprotease inhibitors containing a squaramide moiety ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-09-11 US disclosed
US-20080207607-A1 Heterotricyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-08-28 US disclosed
WO-2007070598-A9 NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS SPRING BANK (US) 2007-11-08 WO disclosed
WO-2007070598-A2 NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS SPRING BANK (US) 2007-06-21 WO disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed